Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma

The recruitment status of this study is unknown because the information has not been verified recently.

Verified March 2007 by Rambam Health Care Campus.
Recruitment status was Recruiting

Sponsor:

Information provided by:

Rambam Health Care Campus

ClinicalTrials.gov Identifier:

NCT00192829

First received: September 13, 2005

Last updated: April 10, 2007

Last verified: March 2007

History of Changes

Purpose

The association between cancer and thrombosis is well known and the occurrence of thrombotic complications is commonly associated with poor prognosis. The aim os this study is to determine the possible value of hypercoagulable parameters as prognostic parameters in advanced non-small cell lung carcinoma (NSCLC).

Condition	Intervention
Non-Small Cell Lung Carcinoma Venous Thromboembolism	Procedure: Blood sample withdrawal

Study Type:	Observational
Study Design:	Additional Descriptors: Convenience Sample Primary Purpose: Screening Time Perspective: Longitudinal Time Perspective: Prospective
Official Title:	Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma

Resource links provided by NLM:

MedlinePlus related topics: Cancer Deep Vein Thrombosis Lung Cancer

U.S. FDA Resources

Further study details as provided by Rambam Health Care Campus:

Estimated Enrollment:	100
Study Start Date:	June 2005

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Histologically or cytologically confirmed diagnosis of NSCLC.
normal serum bilirubin
informed concent to participate in the study

Exclusion Criteria:

anticoagulant therapy
infectious disease

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00192829

Contacts

Contact: Galit Sarig, Ph.D	+972-4-8543503	g_sarig@rambam.health.gov.il
Contact: Nissim Haim, M.D

Locations

Israel
Oncology Institution, Rambam Health Campus	Recruiting
Haifa, Israel
Contact: Nissim Haim, M.D n_haim@rambam.health.gov.il
Principal Investigator: Nissim Haim, M.D
Hematology Laboratory	Recruiting
Haifa, Israel
Contact: Galit Sarig, Ph.D +972-4-8543523 g_sarig@rambam.health.gov.il
Principal Investigator: Galit Sarig, Ph.D

Sponsors and Collaborators

Rambam Health Care Campus

Investigators

Principal Investigator:

Galit Sarig, Ph.D

Rambam Health Care Campus

More Information

Publications:

Haim N, Lanir N, Hoffman R, Haim A, Tsalik M, Brenner B. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med. 2001 Feb 1;110(2):91-6.

Blom JW, Osanto S, Rosendaal FR. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost. 2004 Oct;2(10):1760-5.

Ferrigno D, Buccheri G, Ricca I. Prognostic significance of blood coagulation tests in lung cancer. Eur Respir J. 2001 Apr;17(4):667-73.

ClinicalTrials.gov Identifier:	NCT00192829 History of Changes
Other Study ID Numbers:	Thrombosis and cancer.CTIL
Study First Received:	September 13, 2005
Last Updated:	April 10, 2007
Health Authority:	Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Rambam Health Care Campus:

Lung cancer
Thrombosis
Hypercoagulable

Additional relevant MeSH terms:

Carcinoma
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Thromboembolism
Venous Thromboembolism
Venous Thrombosis
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Carcinoma, Bronchogenic

Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Thrombosis

ClinicalTrials.gov processed this record on May 16, 2013

To Top